1.48

8.03% 0.11

Actuate Therapeutics Inc (ACTU)

Overview News Price History Discussions Forecast

Actuate Therapeutics Inc stock is traded at $1.48, with a volume of 1.32M. It is up +8.03% in the last 24 hours and up +32.14% over the past month. Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Previous Close:

$1.37

Open:

$1.45

24h Volume:

1.32M

Relative Volume:

4.90

Market Cap:

$35.54M

Revenue:

Net Income/Loss:

$-21.54M

P/E Ratio:

-1.4943

EPS:

-0.9904

Net Cash Flow:

$-19.60M

1W Performance:

-10.57%

1M Performance:

+32.14%

6M Performance:

-51.48%

1Y Performance:

-83.03%

1-Day Range:

$1.33

$1.73

1-Week Range:

$1.26

$1.73

52-Week Range:

$0.90

$8.80

Actuate Therapeutics Inc Stock (ACTU) Company Profile

Name

Actuate Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

847-986-4190

Address

1751 RIVER RUN, FORT WORTH

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

ACTU's Discussions on Twitter

Compare ACTU vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACTU Actuate Therapeutics Inc	1.48	29.54M	0	-21.54M	-19.60M	-0.9904
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-26-25	Initiated	B. Riley Securities	Buy
Apr-22-25	Initiated	Craig Hallum	Buy
Mar-17-25	Initiated	H.C. Wainwright	Buy

Actuate Therapeutics Inc Stock (ACTU) Latest News

Aug 21, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm

Aug 21, 2026

Aug 20, 2026

Actuate (ACTU) Results Check: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Closing Reaction: The Stock Gains 16.04% for the Current SessionInvestor Earnings Call - vinanet.vn

Aug 20, 2026

Actuate (ACTU) Results Review: The EPS Result Is Below Expectation in the Available Record; Share Move: Shares Move 0.95% Up at the CloseRevenue Estimate Trend - vinanet.vn

Aug 20, 2026

Aug 18, 2026

Actuate Therapeutics (ACTU) Holds $1.00 After 1.31% Gain, Pinned Between Key Support and ResistanceBullish Percent Index - vinanet.vn

Aug 18, 2026

Actuate Therapeutics stock gets FDA clearance for elraglusib trial By Investing.com - Investing.com Canada

Aug 18, 2026

Aug 16, 2026

Actuate Therapeutics (ACTU) Gains 3.58% to $1.01, Approaches Key Resistance at $1.06Bullish Pattern Stocks - Vinanet

Aug 16, 2026